Takeaway: Stopping effective medical treatment for temporary cosmetic concerns rarely makes sense
Next Steps Building on these results, Aon is continuing to track GLP-1 utilization, pricing and outcomes as new indications, products and financing models emerge
Last reviewed: July 11, 2026 Last updated: July 11, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Clinical evidence shows that discontinuing GLP-1 therapy typically results in weight regain, with patients regaining approximately two-thirds of lost weightincluding abdominal fatwithin one year of stopping
Suppliers operating through anonymous shell accounts or without Canadian business infrastructure have lower overhead but lower accountability